Dr. Zeng is Professor of Biostatistics and Co-Director, Carolina Survey Research Lab at the University of North Carolina at Chapel Hill. He received his PhD from the University of Michigan at Ann Arbor in 2001. Dr. Zeng's current research interests include theoretical development on semiparametric inference and high dimensional data, with particular application to survival data and longitudinal data in biomedical studies.
Dr. Yeh's current research interests include gene expression profiling of human tumors, study of novel therapeutic targets, development of novel therapies, evaluation of novel therapeutics, and pancreatic and colorectal cancer.
Dr. McLeod is Cancer Research Chair, Medical Director of the DeBartolo Family Personalized Medicine Institute, and Senior Member in the Department of Cancer Epidemiology at Moffitt Cancer Center. Dr McLeod is an internationally recognized expert in pharmacogenomics and until joining Moffitt was the Fred Eshelman Distinguished Professor of Pharmacogenomics and Individualized Therapy and founding Director of the Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina at Chapel Hill.
Dr. Liu is Professor of Statistics and Operations Research and Professor of Biostatistics, Carolina Center for Genome Sciences at the University of North Carolina at Chapel Hill. He received is PhD in Statistics from Ohio State University in 2004. Dr. Liu's current research interests include high dimensional data analysis, machine learning, nonparametric statistics, bioinformatics, and cancer genomics.
Dr. Lin is Dennis Gillings Distinguished Professor of Biostatistics and Member of the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Dr. Lin is an internationally-recognized leader in survival analysis and statistical genetics with 20 years of experience in cancer research, currently focused on pharmacogenomics in cancer.
Dr. Cai is Cary C. Boshamer Distinguished Professor and Vice Chair of Biostatistics at the University of North Carolina at Chapel Hill. Dr. Cai is Co-Director of the Biostatistics Service of North Carolina Translational and Clinical Sciences Institute at the University of North Carolina at Chapel Hill and directs the methodology component within that service. Her expertise is in design and analysis of clinical trials and observational studies, longitudinal and survival data analysis, analysis of correlated responses, and missing data/measurement error methods.
Dr. Auman is Director, Tissue Procurement Facility and Research Assistant Professor in the Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina at Chapel Hill. He received his PhD in Pharmacology and Toxicology from Duke University in 2002. Dr. Auman's research interests include gene expression profiling to understand drug response in colorectal cancers.
Dr. Luckett is a statistician helping researchers use data to advance medical science. With expertise in machine learning, big data, and data science, he has collaborated with clinicians and scientists while pursuing his own research in statistical methods for personalized medicine. Dr. Luckett completed a PhD in biostatistics from the University of North Carolina at Chapel Hill in May of 2018.
Dr. Wang is Associate Professor of Biostatistics and Bioinformatics at Duke University. In the past ten years, he has been involved in the design and analysis of cancer clinical trials and translational studies in the Alliance. He serves as Associate Director of Biostatistics and the lead statistician for the Respiratory Committee of the Alliance. Dr. Wang’s methodological research is focused on the development of novel statistical methods for biomarker-integrated cancer clinical trials and for analyzing data from multiple sources subject to lack of generalizability and selection bias.
Dr. Owzar is Professor of Biostatistics and Bioinformatics at Duke University School of Medicine, Director of Bioinformatics at the Duke Cancer Institute, and Director of Biostatistics for the Radiation Countermeasures Center of Research Excellence at Duke. His research is focused on the development of statistical methods and computational tools for investigating the role of heritability on cancer drug induced adverse events. Dr.